title: Categorization of chemicals according to their relative human skin sensitizing potency.
abstract: Although adoption of skin sensitization in vivo assays for hazard identification is likely to be successful in the next few years, this does not replace their use in potency prediction. Notably, measurement of potency of skin sensitizers in the local lymph node assay has been important. However, this local lymph node assay potency measure has not been formally assessed against a range of substances of known human sensitizing potential, because the latter is lacking. Accordingly, criteria for human data have been established that characterize 6 categories of human sensitizing potency, with 1 the most potent and 5 the least potent; category 6 represents true nonsensitizers. The literature has been searched, and 131 chemicals assigned into these categories according to their intrinsic potency judged only by the available human information. The criteria and data set generated provide a basis for examination of the capacity of nonanimal approaches for the determination of human sensitization potency.
authors.affiliation: From the *DABMEB Consultancy Ltd, Sharnbrook, Bedford, UK; †L'Oréal Research & Innovation, Aulnay Sous Bois, France; ‡Shiseido Co, Ltd, Quality Assurance Center, Kanagawa, Japan; §Cosmetics Europe, The Personal Care Association, Brussels, Belgium; ∥Unilever, Safety and Environmental Assurance Centre, Bedford, Sharnbrook, United Kingdom; ¶The Procter & Gamble Company, Darmstadt, Germany; #Chanel, Neuilly sur Seine, France; **Seh Consulting + Services, Paderborn, Germany; ††The Procter & Gamble Company, Strombeek Bever, Belgium; ‡‡Henkel AG & Co KGaA, Düsseldorf, Germany; §§Kao Corporation, Safety Science Research Laboratories, Tochigi, Japan; ∥∥Beiersdorf, Hamburg, Germany; and ¶¶LVMH Recherche, St Jean De Braye Cedex, and ##Laboratoire Pierre Fabre, Castres, France.
authors.forename: David A
authors.initials: DA
authors.lastname: Basketter
authors.forename: Nathalie
authors.initials: N
authors.lastname: Alépée
authors.forename: Takao
authors.initials: T
authors.lastname: Ashikaga
authors.forename: João
authors.initials: J
authors.lastname: Barroso
authors.forename: Nicola
authors.initials: N
authors.lastname: Gilmour
authors.forename: Carsten
authors.initials: C
authors.lastname: Goebel
authors.forename: Jalila
authors.initials: J
authors.lastname: Hibatallah
authors.forename: Sebastian
authors.initials: S
authors.lastname: Hoffmann
authors.forename: Petra
authors.initials: P
authors.lastname: Kern
authors.forename: Silvia
authors.initials: S
authors.lastname: Martinozzi-Teissier
authors.forename: Gavin
authors.initials: G
authors.lastname: Maxwell
authors.forename: Kerstin
authors.initials: K
authors.lastname: Reisinger
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Andreas
authors.initials: A
authors.lastname: Schepky
authors.forename: Magalie
authors.initials: M
authors.lastname: Tailhardat
authors.forename: Marie
authors.initials: M
authors.lastname: Templier
mesh_terms: D000485:Allergens / Q000145:classification* / Q000633:toxicity*; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D023441:Local Lymph Node Assay; D019055:No-Observed-Adverse-Effect Level; D010328:Patch Tests
chemical_list: D000485:Allergens